Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Preventing Alcohol Withdrawal With Oral Baclofen
NCT01937364 · Essentia Health · PHASE2 · terminated · last registry update 2017-05-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The enrollment in the study was too limited for meaningful data analysis.” | – | Registry record, Essentia Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-04-26Results posted on the registry: Washington University School of Medicine, Sodium Oxybate (NCT02063217)
- 2018-03-27Results posted on the registry: Denver Health and Hospital Authority, Baclofen + Placebo (NCT02052440)
- 2018-03-01Results posted on the registry: Wake Forest University Health Sciences, Baclofen + Placebo (NCT01003249)
- 2018-02-26Results posted on the registry: VA Office of Research and Development, baclofen + Desipramine (NCT01265550)
- 2018-02-23Also stopped (withdrawn): Tufts Medical Center, sodium oxybate + placebo (NCT00744393)
- 2018-02-15Results posted on the registry: MedtronicNeuro, intrathecal baclofen (NCT01032239)
- 2017-11-22Results posted on the registry: Kristina Simonyan, Sodium oxybate (NCT01961297)
- 2017-10-24Phase 3 first posted: RVL Pharmaceuticals, Inc., Arbaclofen (NCT03319732)
- 2017-09-25Phase 3 first posted: Kristina Simonyan, Sodium Oxybate (NCT03292458)
- 2017-09-21Phase 3 first posted: RVL Pharmaceuticals, Inc., Arbaclofen + Placebo (NCT03290131)
- 2017-08-29Also stopped (withdrawn): Boston Children's Hospital, Baclofen + placebo (NCT01386255)
- 2017-08-24Results posted on the registry: Alliance for Clinical Trials in Oncology, baclofen/amitriptyline/ketamine gel (NCT00516503)
- 2017-08-16Results posted on the registry: National Institute on Alcohol Abuse and Alcoholism (NIAAA), Baclofen (NCT01751386)
- 2017-06-26Phase 3 first posted: University of Michigan, Multiprofen (NCT03199417)
- 2017-06-14Results posted on the registry: University of Pennsylvania, Baclofen + Placebo (NCT02011516)
- 2017-06-01Results posted on the registry: Stanford University, zolpidem tartrate + sodium oxybate (NCT00383643)
- 2017-05-10Results posted on the registry: New York State Psychiatric Institute, Baclofen + Marijuana (NCT00373295)
- 2017-01-27Results posted on the registry: Sha'ar Menashe Mental Health Center, Baclofen (NCT01002105)
- 2017-01-25Phase 3 first posted: Jazz Pharmaceuticals, JZP-258 (NCT03030599)
- 2017-01-18Phase 3 first posted: Pharnext S.C.A., PXT3003 (NCT03023540)
- 2016-10-06Also stopped (withdrawn): University of Missouri-Columbia, baclofen, intrathecal (NCT01352611)
- 2016-09-08Also stopped (withdrawn): University of Pennsylvania, Baclofen ER + Placebo (NCT02003664)
- 2016-08-17Phase 3 first posted: RVL Pharmaceuticals, Inc., arbaclofen ER Tablets + Placebo for arbaclofen ER tablets (NCT02869425)
- 2016-07-15Results posted on the registry: University of Rochester, Amitriptyline + Baclofen (NCT02099006)
- 2016-05-19Also stopped (terminated): University of Medicine and Dentistry of New Jersey, Placebo + Sodium Oxybate (NCT00498485)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision